Buscar

01/08/2025 Genetic Modifiers in Hereditary and Wild-Type TTR Amyloidosis: Update on Genome-wide Association Study
Vegezzi, E, Quartesan, I, Facchini, S, Curro, R, Mussinelli, R, Palladini, G, Milani, P, Nuvolone, M, Anan, I, Todorova, A, Tournev, I, Hegenbart, U, Schönland, S, Siepen, F, Gillmore, JD, Razvi, Y, Rowczenio, D, Coelho, T, Lemos, C, Alves-Ferreira, M, Mandich, P, Conceicao, I, Marques, W Jr, Tomaselli, P, Alves, G, Planté-Bordeneuve, V, Perrain, V, Hahn, K, Reilly, MM, Houlden, H, Pons, CC, Morales, M, Fabrizi, GM, Tagliapietra, M, Knoll, K, Trenkwalder, T, Cappelli, F, Argirò, A, Arregui, ALD, Agudo, PI, Torrón, RF, Arana-Achaga, X, Goena-Vives, C, Martinez, MLP, Aguirre, MA, Saez, M, Cisneros-Barroso, E, Luigetti, M, Berk, J, Prokaeva, T, Sekijima, Y, Yoshinaga, T, Garcia, SK, Théaudin, M, Guaraldi, P, Gragera, A, Rojas-García, R, Carbayo-Viejo, A, Gonzalez-Duarte, A, Cardenas-Soto, K, Menao, S, Kleopa, K, Zamba-Papanicolaou, E, Christodoulou, C, Waddington-Cruz, M, Foguel, D, Russo, M, Mazzeo, A, Sevilla, T, Sivera, R, Tasaki, M, Ueda, M, Reisin, R, Cejas, LL, Petit, C, Di Stefano, V, Antonini, G, Leonardi, L, Sanchez-Tejerina, D, Manganelli, F, Tozza, S, Pareyson, D, Fenu, S, Briani, C, Salvalaggio, A, Obici, L, Cortese, A. Genetic Modifiers in Hereditary and Wild-Type TTR Amyloidosis: Update on Genome-wide Association Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/06/2025 Safety and efficacy data from the phase 2 ARDA study of empasiprubart in multifocal motor neuropathy
Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, van de Walle, I, Persson, E, Vujcic, M, van de Steen, O, Allen, J, Orazio, EN, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, W. Safety and efficacy data from the phase 2 ARDA study of empasiprubart in multifocal motor neuropathy. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025 Safety and efficacy of riliprubart in chronic inflammatory demyelinating polyneuropathy: 76-week phase 2 trial results
Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and efficacy of riliprubart in chronic inflammatory demyelinating polyneuropathy: 76-week phase 2 trial results. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025 Effect of efgartigimod PH20 SC on lower limb function in chronic inflammatory demyelinating polyneuropathy in ADHERE
Rinaldi, S, Allen, J, Lin, J, Stettner, M, Merkies, I, Guptill, J, Hewamadduma, C, Istas, G, De Roeck, A, Kuwabara, S, Lauria, G, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Echaniz-Laguna, A, Van Hoorick, B, Yamasaki, R, Lewis, R, van Doorn, P. Effect of efgartigimod PH20 SC on lower limb function in chronic inflammatory demyelinating polyneuropathy in ADHERE. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025 Proteomic profiling of Guillain-Barre Syndrome using aptamers: Identifying and Validating Potential Biomarkers
Collet-Vidiella, R, Aguilar, LM, Lleix , C, Caballero-Avila, M, Illa, CT, Go i, EP, Llarch, P, Lluci -Carol, L, Tous, MS, Casasnovas, C, Guti rrez-Guti rrez, G, Fern ndez, JP, Carbayo, A, Gallardo, E, Vesperinas, A, Llanso, L, Fern ndez-Cadenas, I, Querol, L. Proteomic profiling of Guillain-Barre Syndrome using aptamers: Identifying and Validating Potential Biomarkers. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).
01/06/2025 Chat-GPT-4o in diagnosis and management of real-life polyneuropathy cases: Comparative analysis with neurologists
De Lorenzo, A, Moretti, G, Bertini, A, Collet-Vidiella, R, Fasolino, A, Fortanier, E, Hadden, R, Islam, B, Kleopa, K, Cejas, LL, Leonardi, L, Mira, V, Peric, S, Rajabally, Y, Sevilla, T, Tomaselli, P, Tozza, S, Pisciotta, C, Pareyson, D, Nobile-Orazio, E, Doneddu, P. Chat-GPT-4o in diagnosis and management of real-life polyneuropathy cases: Comparative analysis with neurologists. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).